BioMarin Q3 2026 Revenue Jumps 32% to $1.025 Billion
BioMarin posted strong third-quarter results driven by surging metabolic and skeletal condition drug sales, while updating its full-year 2026 outlook.
BioMarin Pharmaceutical reported third-quarter 2026 total revenues of $1.025 billion, a 32% increase compared with the same period a year earlier, according to results released by the company. The performance marked a significant acceleration in top-line growth for the rare-disease drug maker.
The revenue surge was led by a 44% year-over-year jump in sales tied to metabolic conditions, with treatments for skeletal conditions contributing an additional 12% gain over the prior-year quarter. Together, the two therapeutic franchises accounted for the bulk of BioMarin's quarterly momentum.
Read more Deutsche Bank, Ant Digital Map AI Agent Rules for Wholesale Payments →
Despite the strong quarterly showing, the company revised its full-year 2026 guidance downward to account for uncertainty surrounding order timing and the financial impact of two acquired in-process research and development assets. Such acquired R&D charges are standard accounting treatment when a company books pipeline assets obtained through transactions, and they can meaningfully affect reported earnings even when underlying commercial operations remain healthy.
The guidance update reflects a recurring challenge for specialty biopharmaceutical firms: aligning investor expectations with the variable timing of large institutional or government orders, particularly in markets where a small number of buyers can shift quarterly results. Analysts will likely scrutinize whether the order-timing issue represents a structural demand question or a temporary deferral when BioMarin management discusses the results.
Continue reading at All Financial Services & Investing.
